Alnylam Pharmaceuticals
ALNY
#788
Rank
NZ$55.47 B
Marketcap
NZ$414.61
Share price
3.63%
Change (1 day)
-48.07%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$9.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$9.85. In 2025 the company made an earnings per share (EPS) of NZ$3.67.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$9.61161.69%
2025NZ$3.67
2023NZ-$6.29-62%
2022NZ-$16.5529.03%
2021NZ-$12.83-3.36%
2020NZ-$13.28-8.48%
2019NZ-$14.507.67%
2018NZ-$13.4739.74%
2017NZ-$9.6412.94%
2016NZ-$8.5438.84%
2015NZ-$6.15-32.88%
2014NZ-$9.16259.44%
2013NZ-$2.55-31.25%
2012NZ-$3.71

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$11.87 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.39-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$74.68 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.69-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.30-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.16-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$1.12-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ-$5.93-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA